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• This study showed 88% compliance with the hospital policy for use of
Ofirmev among surgical patients from February 2018 until August 2018.
• Statistically significant differences of opioid use between the non-
appropriate group compared to the appropriate group were not evaluated
due to the sample size.
• There were no reported adverse events.
• Limitations of this study: appropriate use was not evaluated for patients
who did not receive Ofirmev
• Future research on this topic should include pain score comparisons.
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• The electronic health record system was used to identify surgical
patients who received at least one dose of Ofirmev from February
2018 until August 2018.
• The following data was collected: patient age, gender, 24-hour post-
operative opioid use in IV morphine equivalents, and reported
adverse events.
Figure 1- A: appropriate use of Ofirmev. 1-B: Opioid usage.
 
 
Table 1: Demographics of Patients  
Gender %    
Male 46  (n = 35) 
Female 54  (n = 40) 
Age 
 25-34 years 11  (n = 8) 
35-44 years 12  (n = 9) 
45-54 years 11  (n = 8) 
55+ years 66  (n = 50) 
Table 2:  Appropriateness of use and opioid useage 
  
24-hour post-operative opioid use in IV 
morphine equivalents 
  
Received Not received Totals 
Use of Ofirmev 
according to hospital 
policy 
Met 48 18 
 
 
66 
Not met 7 2 
 
 
9 
 
Total 55 20 
 
75 
 
• According to multiple randomized controlled trials, intravenous (IV)
acetaminophen (Ofirmev®) has proven to be efficient in managing
postoperative pain, minimizes narcotic use, and is well tolerated [1-
4].
• Dosing for Adults > 50 kg  1000 mg every 6 hours/ 650 mg every 4
hours (maximum of 4000 mg per day)
• Ofirmev was introduced to the WellStar North Fulton Hospital
(WNFH) formulary in February 2018.
• Hospital protocol restricts Ofirmev use to 24 hour doses in
postoperative patients who are not candidates for non-steroidal anti-
inflammatory drug (NSAID) therapy for the relief of mild to moderate
pain, or undergo vertebral fusion surgery to which NSAID therapy
may negatively impact bone healing. Exception: spine surgery
Objective:
• The main purpose of this study is to evaluate the appropriate use of
Ofirmev among surgical patients at WNFH.
Figure 2- A: Number of total dosages of Ofirmev  per each patient.1- B Frequency  of Ofirmev 
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• In total, 75 records were evaluated in this study.
• Baseline characteristics are recorded in table 1.
• This study showed 88% appropriate use with hospital policy.
• There was a higher percentage of opioid use in the non-
appropriateness group compare to appropriateness group (78%
vs. 73%) (table 2)
Table 3: Average number of total dosages of Ofirmev and median 
frequency of Ofirmev (subgroup based on age)
Age
(Years)
Frequency  of Ofirmev
 usage
(Median)
Number of total 
dosages of Ofirmev 
(Mean) 
25-34 years
Q6H 2
35-44 years
Q8H 1.5
45-54 years
Q8H 3.25
55+ years
Q6H 2.5
• Average number of total dosages of Ofirmev  was 2.31.
• Median frequency of Ofirmev was Q6H (table 3).
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